Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.
According to our (Global Info Research) latest study, the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Neuromyelitis Optica Spectrum Disorder (NMOSD) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuromyelitis Optica Spectrum Disorder (NMOSD)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical and Harbour BioMed, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Neuromyelitis Optica Spectrum Disorder (NMOSD) market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Neuromyelitis Optica Spectrum Disorder (NMOSD) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neuromyelitis Optica Spectrum Disorder (NMOSD), with revenue, gross margin and global market share of Neuromyelitis Optica Spectrum Disorder (NMOSD) from 2018 to 2023.
Chapter 3, the Neuromyelitis Optica Spectrum Disorder (NMOSD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neuromyelitis Optica Spectrum Disorder (NMOSD) market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Spectrum Disorder (NMOSD).
Chapter 13, to describe Neuromyelitis Optica Spectrum Disorder (NMOSD) research findings and conclusion.
According to our (Global Info Research) latest study, the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Neuromyelitis Optica Spectrum Disorder (NMOSD) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuromyelitis Optica Spectrum Disorder (NMOSD)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical and Harbour BioMed, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Neuromyelitis Optica Spectrum Disorder (NMOSD) market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Intravenous
- Oral
- Subcutaneous
- Others
- Hospital
- Clinic
- Others
- F. Hoffmann-La Roche Ltd
- Alexion Pharmaceuticals
- RemeGen
- Nihon Pharmaceutical
- Harbour BioMed
- Lundbeck
- Bionure
- Opexa Therapeutics
- TG Therapeutics
- Bio-Thera Solutions
- Boston Pharmaceuticals
- Cour Pharmaceutical
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Neuromyelitis Optica Spectrum Disorder (NMOSD) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neuromyelitis Optica Spectrum Disorder (NMOSD), with revenue, gross margin and global market share of Neuromyelitis Optica Spectrum Disorder (NMOSD) from 2018 to 2023.
Chapter 3, the Neuromyelitis Optica Spectrum Disorder (NMOSD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neuromyelitis Optica Spectrum Disorder (NMOSD) market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Spectrum Disorder (NMOSD).
Chapter 13, to describe Neuromyelitis Optica Spectrum Disorder (NMOSD) research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Neuromyelitis Optica Spectrum Disorder (NMOSD)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neuromyelitis Optica Spectrum Disorder (NMOSD) by Type
1.3.1 Overview: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type in 2022
1.3.3 Intravenous
1.3.4 Oral
1.3.5 Subcutaneous
1.3.6 Others
1.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Application
1.4.1 Overview: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size & Forecast
1.6 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast by Region
1.6.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region, (2018-2029)
1.6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.6 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 F. Hoffmann-La Roche Ltd
2.1.1 F. Hoffmann-La Roche Ltd Details
2.1.2 F. Hoffmann-La Roche Ltd Major Business
2.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.1.4 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.2 Alexion Pharmaceuticals
2.2.1 Alexion Pharmaceuticals Details
2.2.2 Alexion Pharmaceuticals Major Business
2.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.2.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.3 RemeGen
2.3.1 RemeGen Details
2.3.2 RemeGen Major Business
2.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.3.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 RemeGen Recent Developments and Future Plans
2.4 Nihon Pharmaceutical
2.4.1 Nihon Pharmaceutical Details
2.4.2 Nihon Pharmaceutical Major Business
2.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.4.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Nihon Pharmaceutical Recent Developments and Future Plans
2.5 Harbour BioMed
2.5.1 Harbour BioMed Details
2.5.2 Harbour BioMed Major Business
2.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.5.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Harbour BioMed Recent Developments and Future Plans
2.6 Lundbeck
2.6.1 Lundbeck Details
2.6.2 Lundbeck Major Business
2.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.6.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Lundbeck Recent Developments and Future Plans
2.7 Bionure
2.7.1 Bionure Details
2.7.2 Bionure Major Business
2.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.7.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bionure Recent Developments and Future Plans
2.8 Opexa Therapeutics
2.8.1 Opexa Therapeutics Details
2.8.2 Opexa Therapeutics Major Business
2.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.8.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Opexa Therapeutics Recent Developments and Future Plans
2.9 TG Therapeutics
2.9.1 TG Therapeutics Details
2.9.2 TG Therapeutics Major Business
2.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 TG Therapeutics Recent Developments and Future Plans
2.10 Bio-Thera Solutions
2.10.1 Bio-Thera Solutions Details
2.10.2 Bio-Thera Solutions Major Business
2.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.10.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bio-Thera Solutions Recent Developments and Future Plans
2.11 Boston Pharmaceuticals
2.11.1 Boston Pharmaceuticals Details
2.11.2 Boston Pharmaceuticals Major Business
2.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.11.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Boston Pharmaceuticals Recent Developments and Future Plans
2.12 Cour Pharmaceutical
2.12.1 Cour Pharmaceutical Details
2.12.2 Cour Pharmaceutical Major Business
2.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.12.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Cour Pharmaceutical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Neuromyelitis Optica Spectrum Disorder (NMOSD) by Company Revenue
3.2.2 Top 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players Market Share in 2022
3.2.3 Top 6 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players Market Share in 2022
3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Overall Company Footprint Analysis
3.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Region Footprint
3.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Type Footprint
3.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value and Market Share by Type (2018-2023)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2023)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
6.3.2 United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
6.3.3 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
6.3.4 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
7.3.2 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.3 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.5 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.6 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region
8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2018-2029)
8.3.2 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.3 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.5 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.7 Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
9.2 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
9.3 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
9.3.1 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
9.3.2 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
9.3.3 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
10.3.2 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
10.3.4 UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
11.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
11.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Chain
12.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Upstream Analysis
12.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Midstream Analysis
12.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Neuromyelitis Optica Spectrum Disorder (NMOSD)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neuromyelitis Optica Spectrum Disorder (NMOSD) by Type
1.3.1 Overview: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type in 2022
1.3.3 Intravenous
1.3.4 Oral
1.3.5 Subcutaneous
1.3.6 Others
1.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Application
1.4.1 Overview: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size & Forecast
1.6 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast by Region
1.6.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region, (2018-2029)
1.6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.6 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 F. Hoffmann-La Roche Ltd
2.1.1 F. Hoffmann-La Roche Ltd Details
2.1.2 F. Hoffmann-La Roche Ltd Major Business
2.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.1.4 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.2 Alexion Pharmaceuticals
2.2.1 Alexion Pharmaceuticals Details
2.2.2 Alexion Pharmaceuticals Major Business
2.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.2.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.3 RemeGen
2.3.1 RemeGen Details
2.3.2 RemeGen Major Business
2.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.3.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 RemeGen Recent Developments and Future Plans
2.4 Nihon Pharmaceutical
2.4.1 Nihon Pharmaceutical Details
2.4.2 Nihon Pharmaceutical Major Business
2.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.4.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Nihon Pharmaceutical Recent Developments and Future Plans
2.5 Harbour BioMed
2.5.1 Harbour BioMed Details
2.5.2 Harbour BioMed Major Business
2.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.5.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Harbour BioMed Recent Developments and Future Plans
2.6 Lundbeck
2.6.1 Lundbeck Details
2.6.2 Lundbeck Major Business
2.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.6.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Lundbeck Recent Developments and Future Plans
2.7 Bionure
2.7.1 Bionure Details
2.7.2 Bionure Major Business
2.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.7.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bionure Recent Developments and Future Plans
2.8 Opexa Therapeutics
2.8.1 Opexa Therapeutics Details
2.8.2 Opexa Therapeutics Major Business
2.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.8.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Opexa Therapeutics Recent Developments and Future Plans
2.9 TG Therapeutics
2.9.1 TG Therapeutics Details
2.9.2 TG Therapeutics Major Business
2.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 TG Therapeutics Recent Developments and Future Plans
2.10 Bio-Thera Solutions
2.10.1 Bio-Thera Solutions Details
2.10.2 Bio-Thera Solutions Major Business
2.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.10.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bio-Thera Solutions Recent Developments and Future Plans
2.11 Boston Pharmaceuticals
2.11.1 Boston Pharmaceuticals Details
2.11.2 Boston Pharmaceuticals Major Business
2.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.11.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Boston Pharmaceuticals Recent Developments and Future Plans
2.12 Cour Pharmaceutical
2.12.1 Cour Pharmaceutical Details
2.12.2 Cour Pharmaceutical Major Business
2.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
2.12.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Cour Pharmaceutical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Neuromyelitis Optica Spectrum Disorder (NMOSD) by Company Revenue
3.2.2 Top 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players Market Share in 2022
3.2.3 Top 6 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players Market Share in 2022
3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Overall Company Footprint Analysis
3.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Region Footprint
3.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Type Footprint
3.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value and Market Share by Type (2018-2023)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2023)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
6.3.2 United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
6.3.3 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
6.3.4 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
7.3.2 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.3 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.5 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
7.3.6 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region
8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2018-2029)
8.3.2 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.3 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.5 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
8.3.7 Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
9.2 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
9.3 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
9.3.1 South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
9.3.2 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
9.3.3 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2029)
10.3.2 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
10.3.4 UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
11.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
11.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Chain
12.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Upstream Analysis
12.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Midstream Analysis
12.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2024-2029) & (USD Million)
Table 5. F. Hoffmann-La Roche Ltd Company Information, Head Office, and Major Competitors
Table 6. F. Hoffmann-La Roche Ltd Major Business
Table 7. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 8. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Table 10. Alexion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Alexion Pharmaceuticals Major Business
Table 12. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 13. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Alexion Pharmaceuticals Recent Developments and Future Plans
Table 15. RemeGen Company Information, Head Office, and Major Competitors
Table 16. RemeGen Major Business
Table 17. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 18. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. RemeGen Recent Developments and Future Plans
Table 20. Nihon Pharmaceutical Company Information, Head Office, and Major Competitors
Table 21. Nihon Pharmaceutical Major Business
Table 22. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 23. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Nihon Pharmaceutical Recent Developments and Future Plans
Table 25. Harbour BioMed Company Information, Head Office, and Major Competitors
Table 26. Harbour BioMed Major Business
Table 27. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 28. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Harbour BioMed Recent Developments and Future Plans
Table 30. Lundbeck Company Information, Head Office, and Major Competitors
Table 31. Lundbeck Major Business
Table 32. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 33. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Lundbeck Recent Developments and Future Plans
Table 35. Bionure Company Information, Head Office, and Major Competitors
Table 36. Bionure Major Business
Table 37. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 38. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Bionure Recent Developments and Future Plans
Table 40. Opexa Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Opexa Therapeutics Major Business
Table 42. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 43. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Opexa Therapeutics Recent Developments and Future Plans
Table 45. TG Therapeutics Company Information, Head Office, and Major Competitors
Table 46. TG Therapeutics Major Business
Table 47. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 48. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. TG Therapeutics Recent Developments and Future Plans
Table 50. Bio-Thera Solutions Company Information, Head Office, and Major Competitors
Table 51. Bio-Thera Solutions Major Business
Table 52. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 53. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Bio-Thera Solutions Recent Developments and Future Plans
Table 55. Boston Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. Boston Pharmaceuticals Major Business
Table 57. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 58. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Boston Pharmaceuticals Recent Developments and Future Plans
Table 60. Cour Pharmaceutical Company Information, Head Office, and Major Competitors
Table 61. Cour Pharmaceutical Major Business
Table 62. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 63. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Cour Pharmaceutical Recent Developments and Future Plans
Table 65. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million) by Players (2018-2023)
Table 66. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Players (2018-2023)
Table 67. Breakdown of Neuromyelitis Optica Spectrum Disorder (NMOSD) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Neuromyelitis Optica Spectrum Disorder (NMOSD), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Neuromyelitis Optica Spectrum Disorder (NMOSD) Players
Table 70. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Type Footprint
Table 71. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Application Footprint
Table 72. Neuromyelitis Optica Spectrum Disorder (NMOSD) New Market Entrants and Barriers to Market Entry
Table 73. Neuromyelitis Optica Spectrum Disorder (NMOSD) Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Share by Type (2018-2023)
Table 76. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Forecast by Type (2024-2029)
Table 77. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023)
Table 78. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Forecast by Application (2024-2029)
Table 79. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Neuromyelitis Optica Spectrum Disorder (NMOSD) Raw Material
Table 110. Key Suppliers of Neuromyelitis Optica Spectrum Disorder (NMOSD) Raw Materials
Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2024-2029) & (USD Million)
Table 5. F. Hoffmann-La Roche Ltd Company Information, Head Office, and Major Competitors
Table 6. F. Hoffmann-La Roche Ltd Major Business
Table 7. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 8. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Table 10. Alexion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Alexion Pharmaceuticals Major Business
Table 12. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 13. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Alexion Pharmaceuticals Recent Developments and Future Plans
Table 15. RemeGen Company Information, Head Office, and Major Competitors
Table 16. RemeGen Major Business
Table 17. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 18. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. RemeGen Recent Developments and Future Plans
Table 20. Nihon Pharmaceutical Company Information, Head Office, and Major Competitors
Table 21. Nihon Pharmaceutical Major Business
Table 22. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 23. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Nihon Pharmaceutical Recent Developments and Future Plans
Table 25. Harbour BioMed Company Information, Head Office, and Major Competitors
Table 26. Harbour BioMed Major Business
Table 27. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 28. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Harbour BioMed Recent Developments and Future Plans
Table 30. Lundbeck Company Information, Head Office, and Major Competitors
Table 31. Lundbeck Major Business
Table 32. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 33. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Lundbeck Recent Developments and Future Plans
Table 35. Bionure Company Information, Head Office, and Major Competitors
Table 36. Bionure Major Business
Table 37. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 38. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Bionure Recent Developments and Future Plans
Table 40. Opexa Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Opexa Therapeutics Major Business
Table 42. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 43. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Opexa Therapeutics Recent Developments and Future Plans
Table 45. TG Therapeutics Company Information, Head Office, and Major Competitors
Table 46. TG Therapeutics Major Business
Table 47. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 48. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. TG Therapeutics Recent Developments and Future Plans
Table 50. Bio-Thera Solutions Company Information, Head Office, and Major Competitors
Table 51. Bio-Thera Solutions Major Business
Table 52. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 53. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Bio-Thera Solutions Recent Developments and Future Plans
Table 55. Boston Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. Boston Pharmaceuticals Major Business
Table 57. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 58. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Boston Pharmaceuticals Recent Developments and Future Plans
Table 60. Cour Pharmaceutical Company Information, Head Office, and Major Competitors
Table 61. Cour Pharmaceutical Major Business
Table 62. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Solutions
Table 63. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Cour Pharmaceutical Recent Developments and Future Plans
Table 65. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (USD Million) by Players (2018-2023)
Table 66. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Players (2018-2023)
Table 67. Breakdown of Neuromyelitis Optica Spectrum Disorder (NMOSD) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Neuromyelitis Optica Spectrum Disorder (NMOSD), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Neuromyelitis Optica Spectrum Disorder (NMOSD) Players
Table 70. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Type Footprint
Table 71. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Company Product Application Footprint
Table 72. Neuromyelitis Optica Spectrum Disorder (NMOSD) New Market Entrants and Barriers to Market Entry
Table 73. Neuromyelitis Optica Spectrum Disorder (NMOSD) Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Share by Type (2018-2023)
Table 76. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Forecast by Type (2024-2029)
Table 77. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023)
Table 78. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Forecast by Application (2024-2029)
Table 79. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Neuromyelitis Optica Spectrum Disorder (NMOSD) Raw Material
Table 110. Key Suppliers of Neuromyelitis Optica Spectrum Disorder (NMOSD) Raw Materials
LIST OF FIGURES
Figure 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Picture
Figure 2. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type in 2022
Figure 4. Intravenous
Figure 5. Oral
Figure 6. Subcutaneous
Figure 7. Others
Figure 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application in 2022
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Region in 2022
Figure 18. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Players in 2022
Figure 24. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share in 2022
Figure 26. Global Top 6 Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share in 2022
Figure 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Share by Type (2018-2023)
Figure 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share Forecast by Type (2024-2029)
Figure 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Share by Application (2018-2023)
Figure 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share Forecast by Application (2024-2029)
Figure 31. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 41. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Region (2018-2029)
Figure 48. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 51. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 65. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
Figure 66. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
Figure 67. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in 2022
Figure 70. Manufacturing Process Analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Figure 71. Neuromyelitis Optica Spectrum Disorder (NMOSD) Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Picture
Figure 2. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type in 2022
Figure 4. Intravenous
Figure 5. Oral
Figure 6. Subcutaneous
Figure 7. Others
Figure 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application in 2022
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Region in 2022
Figure 18. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Players in 2022
Figure 24. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share in 2022
Figure 26. Global Top 6 Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share in 2022
Figure 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Share by Type (2018-2023)
Figure 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share Forecast by Type (2024-2029)
Figure 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Share by Application (2018-2023)
Figure 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share Forecast by Application (2024-2029)
Figure 31. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 41. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Region (2018-2029)
Figure 48. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 51. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Value (2018-2029) & (USD Million)
Figure 65. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
Figure 66. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
Figure 67. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in 2022
Figure 70. Manufacturing Process Analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Figure 71. Neuromyelitis Optica Spectrum Disorder (NMOSD) Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
